CTOs on the Move


 
BioRx is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Cincinnati, OH. To find more information about BioRx, please visit www.biorx.net
  • Number of Employees: 0-25
  • Annual Revenue: $10-50 Million
  • www.biorx.net
  • 10828 Kenwood Rd
    Cincinnati, OH USA 45242-2812
  • Phone: 866.442.4679

Executives

Name Title Contact Details

Similar Companies

Small Bone Innovations (Main) Corp HQ

Small Bone Innovations, LLC (Main) Corp HQ is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Small Bone Innovations, LLC (Main) Corp HQ is based in New York, NY. You can find more information on Small Bone Innovations, LLC (Main) Corp HQ at www.totalsmallbone.com

Independent Vets

Independent Vets provides relief veterinarians to animal hospitals.

MegaFood

Multivitamins and supplements made with whole food and added nutrients. Non-GMO, organic, vegetarian and certified glyphosate residue free supplements for men, women and kids.

OHCOW

OHCOW is a Windsor, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.